Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Executives said the patient monitoring company’s consumer business will likely become a discontinued operation if it is not ...

Fintel reports that on November 6, 2024, Raymond James upgraded their outlook for Masimo (NasdaqGS:MASI) from Market Perform ...

Masimo Corp. ( (MASI) ) has released its Q3 earnings. Here is a breakdown of the information Masimo Corp. presented to its investors. Masimo ...

Apple convinced a federal jury on Friday that health monitoring tech company Masimo's smartwatches infringe two of its design patents. The jury, in Delaware, agreed with Apple that Masimo's W1 and ...

Needham analyst Michael Matson maintained a Hold rating on Masimo (MASI – Research Report) today. The company’s shares closed ...

Apple and Masimo's patent and trade secret dispute has intensified through lawsuits as Apple defends its innovations and Masimo's claims are rejected in court. Apple and medical equipment maker ...

Apple convinced a federal jury on Friday that early versions of health monitoring tech company Masimo's smartwatches infringe two of its design patents as part of a broader intellectual property ...

The company has discontinued several projects, including noninvasive monitoring of cancer, bilirubin, and diabetes, due to lack of expected progress. Masimo Corp (NASDAQ:MASI) is experiencing ...

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO ...

Masimo Corporation (NASDAQ:MASI) is a global medical technology company specializing in noninvasive patient monitoring technologies. It develops and manufactures monitoring devices, sensors ...

Masimo MASI is set to give its latest quarterly ... and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices ...